Frontier Science has worked in partnership with the Breast International Group (BIG), Breast European Adjuvant Study Team (BrEAST) and in collaboration with Institut de Recherches Internationales SERVIER on the FINESSE trial. The trial was an open, 3-cohort, phase II trial testing oral administration of lucitanib in patients with FGFR1 ER+ metastatic breast cancer.
Frontier Science’s (Scotland) role involved provision of continuous safety and efficacy reports to all committees charged with oversight of the trial, including international regulatory committees.
This trial is now complete and results were published in Clinical Cancer Research in 2020.
